Copyright © Inderes 2011 - present. All rights reserved.

Orion

60.90 EUR

+0.08 %

14,136 following

ORNBV

NASDAQ Helsinki

Biotechnology & Pharmaceuticals

Health Care

+0.08 %
+7.12 %
-7.09 %
-2.79 %
+42.36 %
+35.33 %
+20.26 %
+56.35 %
+442.30 %

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Read more
Market cap
8.6B EUR
Turnover
9.48M EUR
P/E (adj.) (25e)
16.97
EV/EBIT (adj.) (25e)
13.33
P/B (25e)
6.7
EV/S (25e)
4.46
Dividend yield-% (25e)
2.79 %
Coverage
Recommendation
Accumulate
Target price
66.00 EUR
Updated
28.10.2025
Antti Siltanen
Antti Siltanen

Analyst

Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12.2
2026

Annual report '25

24.3
2026

General meeting '26

23.4
2026

Interim report Q1'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
€180M Nubeqa Milestone Payment and Outlook Update: New Outlook Estimate for 2025, issued 3 December 2025 Revenue is estimated to be €1,820–1,900 million. Operating profit is estimated to be €590–670 million. Previous Outlook Estimate for 2025, issued 28 October 2025 Revenue is estimated...
12/3/2025, 7:18 AM
by Ilkka
22
OP reported that Orion’s partner Bayer released its Q3 report and as part of it, Nubeqa’s product sales. Nubeqa’s Q3 sales were 622 million euros, while Bloomberg’s consensus estimate was 575 million euros. A significant beat of estimates creates upward pressure on Q4/25 and next...
11/12/2025, 9:50 AM
by veronmaksaja
20
Quite a roast of Orion, worth watching! A couple of scattered observations: -Speculations about selling or spinning off parts of Orion don’t seem to be the primary projects, even though the uniqueness of the veterinary side was highlighted. For example, Mandatum was like a lion caged...
11/10/2025, 3:14 PM
by PörssiPatruuna
15
First of all, thanks to Verner for the excellent and well-executed Roast format. I have watched many Roasts even from companies that don’t interest me at all, as the format itself is so good. Excellent question suggestions from fellow investors. For me, a big question regarding Orion...
11/9/2025, 1:59 PM
7
Here are Antti’s comments regarding that recent release. Orion announced on Wednesday that it would receive a EUR 180 million milestone payment based on the sales of the prostate cancer drug Nubeqa. The milestone payment is the last lump sum related to Nubeqa and will be recorded...
12/4/2025, 5:43 AM
by Sijoittaja-alokas
6
Right. Strange stock behavior - though the decline seems to have stopped. Bayer, at least, is up about 2%. We await a possible positive profit warning from Orion and hopefully new indications and permission for additional sales next year. At least early-stage prostate cancer (to ...
11/12/2025, 10:56 AM
by Jummijammi2
6
Orion’s CEO Liisa Hurme was talking about the company’s business at the Investor 2025 event Inderes Orion sijoituskohteena | Sijoittaja 2025 - Inderes Aika: 28.11.2025 klo 14.16 Orionin toimitusjohtaja Liisa Hurme kertoo yhtiön liiketoiminnasta Sijoittaja 2025 -tapahtumassa.
11/28/2025, 1:40 PM
by Sijoittaja-alokas
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.